Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Recent developments in monoclonal antibody radiolabeling techniques

Conference ·
OSTI ID:6707609
Monoclonal antibodies (MAbs) have shown the potential to serve as selective carriers of radionuclides to specific in vivo antigens. Accordingly, there has been an intense surge of research activity in an effort to develop and evaluate MAb-based radiopharmaceuticals for tumor imaging (radioimmunoscintigraphy) and therapy (radioimmunotherapy), as well as for diagnosing nonmalignant diseases. A number of problems have recently been identified, related to the MAbs themselves and to radiolabeling techniques, that comprise both the selectivity and the specificity of the in vivo distribution of radiolabeled MAbs. This paper will address some of these issues and primarily discuss recent developments in the techniques for radiolabeling monoclonal antibodies that may help resolve problems related to the poor in vivo stability of the radiolabel and may thus produce improved biodistribution. Even though many issues are identical with therapeutic radionuclides, the discussion will focus mainly on radioimmunoscintigraphic labels. 78 refs., 6 tabs.
Research Organization:
Brookhaven National Lab., Upton, NY (USA)
Sponsoring Organization:
DOE/ER
DOE Contract Number:
AC02-76CH00016
OSTI ID:
6707609
Report Number(s):
BNL-44604; CONF-8911189--1; ON: DE90011201
Country of Publication:
United States
Language:
English

Similar Records

Radiolabeled monoclonal antibodies for imaging and therapy: Potential, problems, and prospects: Scientific highlights
Conference · Tue Dec 31 23:00:00 EST 1985 · OSTI ID:6780378

Improved radioimmunotherapy of hematologic malignancies. Final technical report
Technical Report · Thu Aug 15 00:00:00 EDT 1996 · OSTI ID:373849

Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma
Journal Article · Sun Oct 01 00:00:00 EDT 1989 · Seminars in Nuclear Medicine; (USA) · OSTI ID:5226479